Mechanisms of Candida biofilm drug resistance

Future Microbiology

Volumn 8, Issue 10, 2013, Pages 1325-1337

  Taff, Heather T ^a   Mitchell, Kaitlin F ^a   Edward, Jessica A ^a   Andes, David R ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

antifungal resistance; biofilm; calcineurin; Candida; efflux pumps; extracellular matrix; glucan; persister cells

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; ECHINOCANDIN; FLUCYTOSINE; TRIAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; BIOFILM; CANCER PATIENT; CANDIDA; CELL DENSITY; CELL GROWTH; DRUG EXPOSURE; EFFUSION; EXTRACELLULAR MATRIX; FUNGUS GROWTH; GROWTH CURVE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; QUORUM SENSING; REVIEW; STEROL SYNTHESIS; STRESS;

ANIMALS; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; HUMANS;

EID: 84885002728     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.101     Document Type: Review

References (134)

1. Mah T. Biofilm-specific antibiotic resistance. Future Microbiol. 7(9), 1061-1072 (2012).
2. Romling U, Balsalobre C. Biofilm infections, their resilience to therapy and innovative treatment strategies. J. Intern. Med. 272(6), 541-561 (2012).
3. Fanning S, Mitchell AP. Fungal biofilms. PLoS Pathog. 8(4), e1002585 (2012).
4. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 183(18), 5385-5394 (2001).
5. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol. 11(1), 30-36 (2003).
6. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15(2), 167-193 (2002).
7. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. Candida biofilms: an update. Eukaryot. Cell 4(4), 633-638 (2005).
8. Finkel JS, Mitchell AP. Genetic control of Candida albicans biofilm development. Nat. Rev. Microbiol. 9(2), 109-118 (2011).
9. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48(5), 503-535 (2009).
10. Cornely OA, Bassetti M, Calandra T et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin. Microbiol. Infect. 7, 19-37 (2012).
11. Andes DR, Safdar N, Baddley JW et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin. Infect. Dis. 54(8), 1110-1122 (2012).
12. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Rev. 20, 133-163 (2007).
13. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin. Microbiol. Rev. 17(2), 255-267 (2004).
14. Moran G, Coleman D, Sullivan D. An introduction to the medically important Candida species. In: Candida and Candidiasis. Calderone RA, Clancy CJ (Eds). ASM Press, Washington, DC, USA, 11-27 (2012).
15. Ramage G, Mowat E, Jones B, Williams C, Lopez-Ribot J. Our current understanding of fungal biofilms. Crit. Rev. Microbiol. 35(4), 340-355 (2009).
16. Silva S, Henriques M, Martins A, Oliveira R, Williams D, Azeredo J. Biofilms of non-Candida albicans Candida species: quantification, structure and matrix composition. Med. Mycol. 47(7), 681-689 (2009).
17. Tobudic S, Kratzer C, Lassnigg A, Presterl E. Antifungal susceptibility of Candida albicans in biofilms. Mycoses 55(3), 199-204 (2011).
18. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11(2), 382-402 (1998).
19. Marie C, White TC. Genetic basis of antifungal drug resistance. Curr. Fungal Infect. Rep. 3(3), 163-169 (2009).
20. Ramage G, Rajendran R, Sherry L, Williams C. Fungal biofilm resistance. Int. J. Microbiol. 2012, 528-521 (2012).
21. Kelly SL, Lamb DC, Corran AJ, Baldwin BC, Kelly DE. Mode of action and resistance to azole antifungals associated with the formation of 14a-methylergosta-8,24(28)-dien-3-b,6-a-diol. Biochem. Biophys. Res. Commun. 207, 910-915 (1995).
22. Lupetti A, Danesi R, Campa M, Del Tacca M, Kelly S. Molecular basis of resistance to azole antifungals. Trends Mol. Med. 8, 76-81 (2002).
23. Kelly SL, Lamb DC, Kelly DE et al. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Delta(5,6) desaturation. FEBS Lett. 400, 80-82 (1997).
24. Shimokawa O, Nakayama H. Increased sensitivity of Candida albicans cells accumulating 14a-methylated sterols to active oxygen: possible relevance to in vivo efficacies of azole antifungal agents. Antimicrob. Agents Chemother. 36, 1626-1629 (1992).
25. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds C, Rex JH. An insight into the antifungal pipeline: selected new molecules and beyond. Nat. Rev. Drug Discov. 9, 719-727 (2010).
26. Cleveland AA, Farley MM, Harrison LH et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin. Infect. Dis. 55(10), 1352-1361 (2012).
27. Law D, Moore CB, Wardle HM, Ganguli LA, Keaney MG, Denning DW. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J. Antimicrob. Chemother. 34, 659-668 (1994).
28. White TC. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14-a-de-methylase in Candida albicans. Antimicrob. Agents Chemother. 41, 1488-1494 (1997).
29. Lamb DC, Kelly DE, Schunck WH. The mutation T315A in Candida albicans sterol 14a-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J. Biol. Chem. 272, 5682-5688 (1997).
30. Sanglard D, Ischer F, Koymans L, Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14a-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42, 241-253 (1998).
31. Marichal PK, Willemsens L, Bellens S et al. Contribution of mutations in the cytochrome P450 14a-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145(10), 2701-2713 (1999).
32. Sanglard D, Kuchler K, Ischer Pagani JL, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39(11), 2378-2386 (1995).
33. Albertson GD, Niimi M, Cannon RD, Jenkinson HF. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob. Agents Chemother. 40, 2835-2841 (1996).
34. White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from an HIV-infected patient. Antimicrob. Agents Chemother. 41, 1482-1487 (1997).
35. Vanden Bossche H, Marichal P, Odds FC, Le June L, Coene MC. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob. Agents Chemother. 36, 2602-2610 (1992).
36. Marichal PVB, Odds H, Nobels FC et al. Molecular-biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob. Agents Chemother. 41, 2229-2237 (1997).
37. Coste AT, Selmecki A, Forche A et al. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot. Cell 6(10), 1889-1904 (2007).
38. Silva AP, Miranda IM, Guida A et al. Transcriptional profiling of azole-resistant Candida parapsilosis strains. Antimicrob. Agents Chemother. 55(7), 3546-3556 (2011).
39. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob. Agents Chemother. 49(2), 668-679 (2005).
40. Cannon RD, Lamping E, Holmes AR et al. Efflux-mediated antifungal drug resistance. Clin. Microbiol. Rev. 22(2), 291-321 (2009).
41. Bizerra FC, Nakamura CV, de Poersch C et al. Characteristics of biofilm formation by Candida tropicalis and antifungal resistance. FEMS Yeast Res. 8(3), 442-450 (2008).
42. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45(9), 2475-2479 (2001).
43. Lamfon HPS, McCullough M, Pratten J. Susceptibility of Candida albicans biofilms grown in a constant depth film fermentor to chlorhexidine, fluconazole and miconazole: a longitudinal study. J. Antimicrob. Chemother. 53, 383-385 (2004).
44. Gray KC, Palacios DS, Dailey I et al. Amphotericin primarily kills yeast by simply binding ergosterol. Proc. Natl Acad. Sci. USA. 109(7), 2234-2239 (2012).
45. Kelly SL, Lamb DC, Kelly DE, Loeffler J, Einsele H. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 348, 1523-1524 (1996).
46. Vandeputte P, Tronchin G, Berges T, Hennequin C, Chabasse D, Bouchara JP. Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth. Antimicrob. Agents Chemother. 51(3), 982-990 (2007).
47. Tobudic S, Kratzer C, Lassnigg A, Graninger W, Presterl E. In vitro activity of antifungal combinations against Candida albicans biofilms. J. Antimicrob. Chemother. 65(2), 271-274 (2009).
48. Denning DW. Echinocandin antifungal drugs. Lancet 362, 1142-1151 (2003).
49. Perlin D. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10(3), 121-130 (2007).
50. Shapiro RS, Robbins N, Cowen LE. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol. Mol. Biol. Rev. 75(2), 213-267 (2011).
51. Chaffin WL, Lopez-Ribot JL, Casanova M, Gozalbo D, Martinez JP. Cell wall and secreted proteins of Candida albicans: identification, function, and expression. Microbiol. Mol. Biol. Rev. 62(1), 130-180 (1998).
52. Hernandez S, Lopez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill Jr. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. 48(4), 1382-1383 (2004).
53. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 50, 2058-2063 (2006).
54. Desnos-Ollivier MB, Raoux S, Hoinard D, Dromer D, Dannaoui FE. European Committee on Antibiotic Susceptibility Testing. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52(9), 3092-3098 (2008).
55. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57(4), 705-708 (2006).
56. Park S, Kelly R, Kahn JN et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49(8), 3264-3273 (2005).
57. Zimbeck AJ, Iqbal N, Ahlquist AM et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob. Agents Chemother. 54(12), 5042-5047 (2010).
58. Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for b-1,6-glucan synthesis inhibition by caspofungin. Antimicrob. Agents Chemother. 50, 3160-3161 (2006).
59. Bizerra FC, Melo AS, Katchburian E et al. Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species. Antimicrob Agents Chemother, 55(1), 302-310 (2011).
60. Tobudic S, Kratzer C, Lassnigg A, Graninger W, Presterl E. In vitro activity of antifungal combinations against Candida albicans biofilms. J. Antimicrob. Chemother. 65(2), 271-274 (2010).
61. Nett JE, Crawford K, Marchillo K, Andes DR. Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob. Agents Chemother. 54(8), 3505-3508 (2010).
62. Hope W, Tabernero L, Denning DW, Anderson MJ. Molecular mechanisms of primary resistance to flucytosice in Candida albicans. Antimicrob. Agents Chemother. 48(11), 4377-4386 (2004).
63. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2, 73-85 (2002).
64. Vanden Bossche H, Marichal P, Odds F. Molecular mechanisms of drug resistance in fungi. Trends Microbiol. 2(10), 393-400 (1994).
65. Morschhauser J. The genetic basis of fluconazole resistance development in Candida albicans. Biochim. Biophys. Acta 1587, 240-248 (2002).
66. Bachmann SP, Patterson TF, Lopez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J. Clin. Microbiol. 40, 2228-2230 (2002).
67. Niimi K, Maki K, Ikeda F et al. Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility. Antimicrob. Agents Chemother. 50(4), 1148-1155 (2006).
68. Silver PM, Oliver BG, White TC. Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistance. Med. Mycol. 46(3), 231-239 (2008).
69. Schubert S, Barker KS, Znaidi S et al. Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans. Antimicrob. Agents Chemother. 55(5), 2212-2223 (2011).
70. Coste A. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 172, 2139-2156 (2006).
71. Dunkel N, Blass J, Rogers D, Morschhauser J. Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans isolate. Mol. Microbiol. 69, 827-840 (2008).
72. Ramage G, Bachmann S, Patterson TF, Wickes BL, Lopez-Ribot JL. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J. Antimicrob. Chemother. 49, 973-980 (2002).
73. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect. Immun. 71, 4333-4340 (2003).
74. Nett JE, Lepak AJ, Marchillo K, Andes DR. Time course global gene expression analysis of an in vivo Candida biofilm. J. Infect. Dis. 200(2), 307-313 (2009).
75. Nett JE, Lepak AJ, Marchillo K, Andes DR. Time course global gene expression analysis of an in vivo Candida biofilm. J. Infect. Dis. 200(2), 307-313 (2009).
76. Duguid IG, Evans E, Brown MR, Gilbert P. Effect of biofilm culture upon the susceptibility of Staphylococcus epidermidis to tobramycin. J. Antimicrob. Chemother. 30(6), 803-810 (1992).
77. Evans DJ, Allison DG, Brown MR, Gilbert P. Susceptibility of Pseudomonas aeruginosa and Escherichia coli biofilms towards ciprofloxacin: effect of specific growth rate. J. Antimicrob. Chemother. 27(2), 177-184 (1991).
78. Baillie GS, Douglas JL. Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents. Antimicrob. Agents Chemother. 42, 1900-1905 (1998).
79. Baillie GS, Douglas LJ. Iron-limited biofilms of Candida albicans and their susceptibility to amphotericin B. Antimicrob. Agents Chemother. 42(8), 2146-2149 (1998).
80. Perumal PMS, Chaffin WL. Role for cell density in antifungal drug resistance in Candida albicans biofilms. Antimicrob. Agents Chemother. 7, 2454-2463 (2007).
81. Seneviratne CJ, Jin LJ, Samaranayake YH, Samaranayake LP. Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms. Antimicrob. Agents Chemother. 8, 3259-3266 (2008).
82. Alem MA, Flowers TH, Douglas LJ. Production of tyrosol by Candida albicans biofilms and its role in quorum sensing and biofilm development. Eukaryot. Cell 5(10), 1770-1779 (2006).
83. Chen H, Fujita M, Feng Q, Clardy J, Fink GR. Tyrosol is a quorum sensing molecule in Candida albicans. Proc. Natl Acad. Sci. USA 101, 5048-5052 (2004).
84. Hornby JM, Jensen EC, Lisec AD et al. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl. Environ. Microbiol. 67, 2982-2992 (2001).
85. Ramage G, Saville SP, Wickes BL, Lopez-Ribot JL. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl. Environ. Microbiol. 68, 5459-5463 (2002).
86. Jabra-Rizk MA, SM, James C, Meiller T. Effect of farnesol on Candida dubliniensis biofilm formation and fluconazole resistance. FEMS Yeast Res. 6(7), 1063-1073 (2006).
87. Weber K, Schulz B, Ruhnke M. The quorum-sensing molecule E,E-farnesol-its variable secretion and its impact on the growth and metabolism of Candida species. Yeast 27(9), 727-739 (2010).
88. Cao YY, Cao YB, Xu Z et al. cDNA microarray analysis of differential gene expression in Candida albicans biofilm exposed to farnesol. Antimicrob. Agents Chemother. 49, 584-589 (2005).
89. Flemming HC, Wingender J. The biofilm matrix. Nat. Rev. Microbiol. 8(9), 623-633 (2010).
90. Baillie GS, Douglas LJ. Matrix polymers of Candida biofilms and their possible resistance to antifungal agents. J. Antimicrob. Chemother. 46, 397-403 (2000).
91. Al-Fattani MA, Douglas LJ. Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J. Med. Microbiol. 55(Pt 8), 999-1008 (2006).
92. Nett J, Lincoln L, Marchillo K et al. Putative role of b-1,3 glucans in Candida albicans biofilm resistance. Antimicrob. Agents Chemother. 51(2), 510-520 (2007).
93. Nett JE, Sanchez H, Cain MT, Andes DR. Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J. Infect. Dis. 202(1), 171-175 (2010).
94. Taff HT, Nett JE, Zarnowski R et al. A Candida biofilm-induced pathway for matrix delivery: implications for drug resistance. PLoS Pathog. 8(8), e1002848 (2012).
95. Vediyappan G, Rossignol T, d'Enfert C. Interaction of Candida albicans biofilms with antifungals: transcriptional response and binding of antifungals to b-glucans. Antimicrob. Agents Chemother. 54(5), 2096-2111 (2010).
96. Nett JE, Crawford K, Marchillo K, Andes DR. Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob. Agents Chemother. 54(8), 3505-3508 (2010).
97. Mitchell K, Taff H, Cuevas M, Reinicke E, Sanchez H, Andes D. Role of matrix b-1,3 glucan in antifungal resistance of non-albicans Candida biofilms. Antimicrob. Agents Chemother. 57(4), 1918-1920 (2013).
98. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin b lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46(6), 1773-1780 (2002).
99. Nett JE, Sanchez H, Cain MT, Ross KM, Andes DR. Interface of Candida albicans biofilm matrix-associated drug resistance and cell wall integrity regulation. Eukaryot. Cell 10(12), 1660-1669 (2011).
100. Nobile CJ, Nett JE, Hernday AD et al. Biofilm matrix regulation by Candida albicans Zap1. PLoS Biol. 7(6), e1000133 (2009).
101. Martins M, Uppuluri P, Thomas DP et al. Presence of extracellular DNA in the Candida albicans biofilm matrix and its contribution to biofilms. Mycopathologia 169(5), 323-331 (2010).
102. Martins M, Henriques M, Lopez-Ribot JL, Oliveira R. Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses 55(1), 80-85 (2012).
103. Itzek A, Zheng L, Chen Z, Merritt J, Kreth J. Hydrogen peroxide-dependent DNA release and transfer of antibiotic resistance genes in Streptococcus gordonii. J. Bacteriol. 193(24), 6912-6922 (2011).
104. Montanaro L, Poggi A, Visai L et al. Extracellular DNA in biofilms. Int. J. Artif. Organs. 34(9), 824-831 (2011).
105. Sahni N, Yi S, Daniels KJ, Srikantha T, Pujol C, Soll DR. Genes selectively up-regulated by pheromone in white cells are involved in biofilm formation in Candida albicans. PLoS Pathog. 5(10), e1000601 (2009).
106. Yi S, Sahni N, Daniels KJ et al. Alternative mating type configurations (a/a versus a/a or a/a) of Candida albicans result in alternative biofilms regulated by different pathways. PLoS Biol. 9(8), e1001117 (2011).
107. LaFleur MD, Kumamoto CA, Lewis K. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob. Agents Chemother. 50(11), 3839-3846 (2006).
108. Lewis K. Multidrug tolerance of biofilms and persister cells. Curr. Top. Microbiol. Immunol. 332, 107-131 (2008).
109. Khot PD, Suci PA, Miller RL, Nelson RD, Tyler BJ. A small subpopulation of blastospores in Candida albicans biofilms exhibit resistance to amphotericin B associated with differential regulation of ergosterol and b-1,6-glucan pathway genes. Antimicrob. Agents Chemother. 50, 3708-3716 (2006).
110. Al-Dhaheri RS, Douglas LJ. Absence of amphotericin B-tolerant persister cells in biofilms of some Candida species. Antimicrob. Agents Chemother. 52(5), 1884-1887 (2008).
111. Lafleur MD, Qi Q, Lewis K. Patients with longterm oral carriage harbor high-persister mutants of Candida albicans. Antimicrob. Agents Chemother. 54(1), 39-44 (2010).
112. Kumamoto CA. A contact-activated kinase signals Candida albicans invasive growth and biofilm development. Proc. Natl Acad. Sci. USA 102(15), 5576-5581 (2005).
113. Uppuluri P, Nett J, Heitman J, Andes D. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob. Agents Chemother. 52(3), 1127-1132 (2008).
114. Robbins N, Uppuluri P, Nett J et al. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog. 7(9), e1002257 (2011).
115. Bink A, Vandenbosch D, Coenye T, Nelis H, Cammue BP, Thevissen K. Superoxide dismutases are involved in Candida albicans biofilm persistence to miconazole. Antimicrob. Agents Chemother. 55(9), 4033-4037 (2011).
116. Vandenbosch D, Braeckmans K, Nelis HJ, Coenye T. Fungicidal activity of miconazole against Candida spp. biofilms. J. Antimicrobial. Chemother. 65(4), 694-700 (2010).
117. Ghosh S, Kebaara BW, Atkin AL, Nickerson KW. Regulation of aromatic alcohol production in Candida albicans. Appl. Environ. Microbiol. 74, 7211-7218 (2008).
118. Yu LH, Wei X, Ma M, Chen XJ, Xu SB. Possible inhibitory molecular mechanism of farnesol on the development of fluconazole resistance in Candida albicans biofilm. Antimicrob. Agents Chemother. 56(2), 770-775 (2012).
119. Sharma M, Prasad R. The quorum-sensing molecule farnesol is a modulator of drug efflux mediated by ABC multidrug transporters and synergizes with drugs in Candida albicans. Antimicrob. Agents Chemother. 55, 4834-4843 (2011).
120. Brackman GCP, Maes L, Nelis HJ, Coenye T. Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. Antimicrob. Agents Chemother. 55(6), 2655-2661 (2011).
121. Hogan DA. Talking to themselves: autoregulation and quorum sensing in fungi. Eukaryot. Cell 5(4), 613-619 (2006).
122. Uppuluri P, Chaturvedi AK, Srinivasan A et al. Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog. 6(3), e1000828 (2010).
123. Kucharikova S, Sharma N, Spriet I, Maertens J, Van Dijck P, Lagrou K. Activities of systemically administered echinocandins against in vivo mature Candida albicans biofilms developed in a rat subcutaneous model. Antimicrob. Agents Chemother. 57(5), 2365-2368 (2013).
124. Tobudic S, Lassnigg A, Kratzer C, Graninger W, Presterl E. Antifungal activity of amphotericin B, caspofungin and posaconazole on Candida albicans biofilms in intermediate and mature development phases. Mycoses 53(3), 208-214 (2010).
125. Mukherjee PK, Long L, Kim HG, Ghannoum MA. Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms. Int. J. Antimicrob. Agents 33(2), 149-153 (2009).
126. Ullmann AJ, Akova M, Herbrecht R et al. ESCMID* guideline for the diagnosis and management of Candida dis. 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin. Microbiol. Infect. 7, 53-67 (2012).
127. Chang W, Li Y, Zhang L, Cheng A, Liu Y, Lou H. Retigeric acid B enhances the efficacy of azoles combating the virulence and biofilm formation of Candida albicans. Biol. Pharm. Bull. 35(10), 1794-1801 (2012).
128. Pulcrano G, Panellis D, De Domenico G, Rossano F, Catania MR. Ambroxol influences voriconazole resistance of Candida parapsilosis biofilm. FEMS Yeast Res. 12(4), 430-438 (2012).
129. Khan MS, Ahmad I. Antibiofilm activity of certain phytocompounds and their synergy with fluconazole against Candida albicans biofilms. J. Antimicrob. Chemother. 67(3), 618-621 (2012).
130. Chen YL, Brand A, Morrison EL et al. Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis. Eukaryot. Cell 10(6), 803-819 (2011).
131. LaFleur MD, Lucumi E, Napper AD, Diamond SL, Lewis K. Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms. J. Antimicrob. Chemother. 66(4), 820-826 (2011).
132. Wei G-X, Xu X, Wu CD. In vitro synergism between berberine and miconazole against planktonic and biofilm Candida cultures. Arch. Oral Biol. 56(6), 565-572 (2011).
133. Shi W, Chen Z, Chen X, Cao L, Liu P, Sun S. The combination of minocycline and fluconazole causes synergistic growth inhibition against Candida albicans: an in vitro interaction of antifungal and antibacterial agents. FEMS Yeast Res. 10(7), 885-893 (2010).
134. Micell MH, Bernardo SM, Lee SA. In vitro analyses of the combination of high-dose doxycycline and antifungal agents against Candida albicans biofilms. Int. J. Antimicrob. Agents 34(4), 326-332 (2009).